# Role of Finerenone in African American Veterans With Diabetic Kidney Disease

> **NCT07155694** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Washington D.C. Veterans Affairs Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** Finerenone 10 MG
- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT07155694
- **Lead sponsor:** Washington D.C. Veterans Affairs Medical Center
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2027-07
- **Final completion:** 2027-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07155694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07155694, "Role of Finerenone in African American Veterans With Diabetic Kidney Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07155694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*